PROCEPT BioRobotics (NASDAQ:PRCT) Director Buys $3,781,878.03 in Stock

Key Points

• Director Antal Rohit Desai bought roughly 426,262 shares across March 5–9 (about $10.5M), sharply increasing his stake and signaling strong insider bullishness.
• PROCEPT missed quarterly estimates—reporting ($0.53) EPS vs. ($0.32) expected and $76.38M revenue vs. $93.70M expected—while posting a negative net margin of ~31% despite 11.9% YoY revenue growth.
• Two law firms have launched securities‑fraud investigations into the company’s prior guidance/comments, creating legal risk amid mixed analyst coverage (average rating: "Hold", average price target ~$40.82) and very high institutional ownership (~89%).

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) Director Antal Rohit Desai bought 160,317 shares of PROCEPT BioRobotics stock in a transaction on Friday, March 6th. The stock was acquired at an average price of $23.59 per share, for a total transaction of $3,781,878.03. Following the purchase, the director owned 327,563 shares of the company's stock, valued at approximately $7,727,211.17. This trade represents a 95.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Antal Rohit Desai also recently made the following trade(s):

• On Monday, March 9th, Antal Rohit Desai bought 98,699 shares of PROCEPT BioRobotics stock. The shares were acquired at an average price of $24.55 per share, with a total value of $2,423,060.45.
• On Thursday, March 5th, Antal Rohit Desai bought 167,246 shares of PROCEPT BioRobotics stock. The shares were bought at an average cost of $25.58 per share, with a total value of $4,278,152.68.

PROCEPT BioRobotics Trading Up 4.3%

Shares of NASDAQ PRCT traded up $1.04 during mid-day trading on Monday, reaching $25.26. The company had a trading volume of 2,163,428 shares, compared to its average volume of 1,640,943. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -14.77 and a beta of 1.03. PROCEPT BioRobotics Corporation has a 52 week low of $19.35 and a 52 week high of $66.85. The business's 50-day moving average is $29.11 and its 200-day moving average is $32.83. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.21). The company had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.35) EPS. Equities analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PRCT shares. Robert W. Baird started coverage on PROCEPT BioRobotics in a report on Friday. They issued a "neutral" rating and a $30.00 price target for the company. TD Cowen reduced their price objective on PROCEPT BioRobotics from $50.00 to $34.00 and set a "buy" rating on the stock in a report on Thursday, February 26th. Morgan Stanley lowered their target price on PROCEPT BioRobotics from $56.00 to $51.00 and set an "overweight" rating for the company in a report on Tuesday, December 2nd. UBS Group began coverage on PROCEPT BioRobotics in a research report on Friday, December 12th. They set a "buy" rating and a $62.00 price target on the stock. Finally, Jefferies Financial Group downgraded PROCEPT BioRobotics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 26th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, PROCEPT BioRobotics has an average rating of "Hold" and an average price target of $40.82.

Institutional Investors Weigh In On PROCEPT BioRobotics

Hedge funds have recently modified their holdings of the business. Alliancebernstein L.P. boosted its stake in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company's stock valued at $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company's stock worth $102,919,000 after buying an additional 1,218,815 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in PROCEPT BioRobotics by 23.3% during the third quarter. Westfield Capital Management Co. LP now owns 1,970,147 shares of the company's stock worth $70,315,000 after buying an additional 371,798 shares during the period. Mackenzie Financial Corp lifted its holdings in PROCEPT BioRobotics by 8.2% during the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company's stock worth $49,512,000 after buying an additional 118,971 shares during the period. Finally, Chicago Capital LLC boosted its position in PROCEPT BioRobotics by 175.7% during the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company's stock valued at $55,992,000 after acquiring an additional 999,873 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.